Related Experiment Video

Updated: Oct 12, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

New and emerging lipid-modifying drugs to lower LDL cholesterol

Constantine E Kosmas1,2, Dafni Pantou3, Andreas Sourlas4

  • 1Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA.

Drugs in Context
|November 19, 2021
PubMed

Insights

New drugs offer hope for lowering LDL-cholesterol (low-density lipoprotein-cholesterol) when statins are insufficient. These emerging therapies target cardiovascular disease (CVD) risk for better patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Atherosclerosis Research

Background:

  • Cardiovascular disease (CVD) remains the leading global cause of mortality.
  • Low-density lipoprotein-cholesterol (LDL-C) is integral to atherosclerosis and CVD development.
  • Statins are primary treatments for hypercholesterolemia, effectively reducing LDL-C and CVD risk, but patient adherence and efficacy can be limited.

Purpose of the Study:

  • To review current clinical and scientific data on novel LDL-C lowering agents.
  • To discuss emerging lipid-modifying drugs beyond statins.
  • To highlight therapeutic options for patients not achieving LDL-C goals or intolerant to statins.

Main Methods:

  • Literature review of clinical trials and scientific studies.
  • Analysis of data on novel LDL-C lowering agents.
  • Discussion of emerging drug classes including PCSK9 inhibitors, bempedoic acid, inclisiran, ANGPTL3 inhibitors, PPARβ/δ agonists, and LXR agonists.

Main Results:

  • Several novel agents demonstrate promising LDL-C lowering capabilities.
  • Emerging therapies offer alternative or complementary strategies to statins.
  • These drugs show potential for improving CVD risk management in diverse patient populations.

Conclusions:

  • Novel LDL-C lowering drugs represent a significant advancement in managing hypercholesterolemia and reducing cardiovascular risk.
  • These agents provide crucial alternatives for patients with statin intolerance or suboptimal response.
  • Further research and clinical application of these emerging therapies are essential for optimizing cardiovascular health outcomes.

Keywords:
ANGPTL3 inhibitorsLDL-C-loweringLXR agonistsPCSK9 inhibitorsPPARβ/δ agonistsbempedoic acidcardiovascular diseaseinclisiran

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.6K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
946
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
670
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
12
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
1.1K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
735